CUE
- Cue Biopharma, Inc.
()
Overview
Company Summary
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company that focuses on developing a new class of biologics called Immuno-STATs. These Immuno-STATs are designed to selectively engage and modulate disease-relevant immune responses in various therapeutic areas.
The company's technology platform, called the Immuno-STAT (Selective Targeting and Alteration of T cells) platform, leverages the power of the body's immune system to create novel therapies. Cue Biopharma's approach involves designing and engineering molecules that can target specific proteins on the surface of T cells, a type of immune cell. By selectively activating or inhibiting these T cells, Cue aims to modulate immune responses and effectively treat specific diseases.
Cue Biopharma focuses on developing therapies for various medical conditions, including cancer, autoimmune diseases, and infectious diseases. The customizable nature of their Immuno-STAT platform allows for the creation of therapies tailored to target specific diseases and patient populations.
Through collaborations and partnerships, Cue Biopharma aims to apply its Immuno-STAT platform to develop innovative treatments for unmet medical needs. The company's ultimate goal is to revolutionize the treatment of diseases by harnessing the power of the immune system and bringing novel therapies to patients.